

学位論文

**Effects of the novel nonsteroidal mineralocorticoid receptor blocker,
esaxerenone (CS-3150), on blood pressure and urinary
angiotensinogen in low-renin Dahl salt-sensitive hypertensive rats**

香川大学大学院医学系研究科

分子情報制御医学系専攻

李 磊

Effects of the novel nonsteroidal mineralocorticoid receptor blocker, esaxerenone (CS-3150), on blood pressure and urinary angiotensinogen in low-renin Dahl salt-sensitive hypertensive rats

Lei Li¹, Yu Guan¹, Hiroyuki Kobori², Asahiro Morishita³, Hideki Kobara³, Tsutomu Masaki³, Daisuke Nakano¹, Akira Nishiyama¹

¹Departments of Pharmacology, and ³Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Kagawa, Japan

²Departments of Pharmacology and Nephrology, Faculty of Medicine, International University of Health and Welfare, Narita, Japan

Short title: Esaxerenone in low-renin salt-dependent hypertension

Grants: This was in part a collaborative study with Daiichi-Sankyo Co., Ltd. (to A.N.). The funders had no role in the study design, data collection and analysis,

decision to publish, or preparation of the manuscript. This study was also supported in part by the Salt Sciences Foundation (to A.N.).

Address for reprints and all other communications:

Akira Nishiyama, MD, PhD.

Department of Pharmacology, Faculty of Medicine, Kagawa University

1750-1 Miki-cho, Kita-gun, Kagawa 761-0793, Japan

Tel: +81 87 891 2125

Fax: +81 87 891 2126

E-mail: akira@med.kagawa-u.ac.jp

Abstract

Herein, we studied the effects of the novel nonsteroidal selective mineralocorticoid receptor (MR) blocker, esaxerenone, on blood pressure and renal injury in Dahl salt-sensitive (DSS) rats. We also monitored the urinary intact and total angiotensinogen (AGT). DSS rats were given a normal salt diet (NS: 0.4% NaCl, n = 10), high salt diet (HS: 8% NaCl, n = 10), HS + esaxerenone (1 mg/kg/day, p.o., n = 10), or HS + losartan (angiotensin II receptor blocker, 10 mg/kg/day, p.o., n = 10) for 6 weeks. Glomerular and tubulointerstitial tissues were obtained by a laser capture method. HS-treated DSS rats developed hypertension, albuminuria and glomerular injury, which were associated with increased glomerular desmin staining and reduced mRNA levels of glomerular *podocin* and *nephrin*. HS-treated DSS rats also showed tubulointerstitial fibrosis with an increase in renal oxidative stress (4-hydroxynonenal staining). The urinary (total AGT – intact AGT)/intact AGT ratio, an indicator of intrarenal renin activity, was significantly suppressed in

HS-treated DSS rats. Treatment with esaxerenone significantly decreased blood pressure, while losartan did not. Furthermore, esaxerenone attenuated the development of albuminuria, glomerular injury and tubulointerstitial fibrosis more than losartan did, and this was associated with reduced renal oxidative stress. These data indicate that esaxerenone induces antihypertensive and renal protective effects in salt-dependent hypertensive mice with suppressed intrarenal renin activity, as indicated by low levels of the urinary (total AGT – intact-AGT)/intact AGT ratio.

Keywords

nonsteroidal mineralocorticoid receptor (MR) blocker, esaxerenone, Dahl salt-sensitive (DSS) rats, intrarenal renin activity, angiotensinogen (AGT)

Introduction

Inappropriate activation of mineralocorticoid receptor (MR) contributes to the development of salt-dependent hypertension and renal injury [1-3]. Recent studies have revealed that high salt (HS) induces salt-sensitive hypertension in Dahl salt-sensitive (DSS) rats in a ligand-independent manner through Rac-1-dependent MR activation [4]. Treatment with steroidal MR antagonists, such as spironolactone and eplerenone, effectively decreased blood pressure in DSS hypertensive rats [5-7], although their plasma aldosterone levels were very low [5, 6]. A double-blind crossover trial also revealed that in hypertensive patients who showed low-renin and normal plasma potassium levels, spironolactone was a more effective natriuretic antihypertensive agent compared with amiloride, losartan and thiazide [8]. These data indicate that MR is a potential therapeutic target for salt-dependent hypertension.

Because salt-dependent hypertension is a major risk factor for renal injury and cardiovascular disease [1, 9], it is important to clinically diagnose these patients.

In this regard, subjects with salt-dependent hypertension usually show a suppressed renin-angiotensin system (RAS) due to reduced renin release from juxtaglomerular cells [10]. Consistently, HS intake markedly decreased plasma angiotensin II levels, which was accompanied by reduced plasma renin activity (PRA) [10]. Furthermore, blockade of the RAS with angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) was less effective in decreasing blood pressure in low-renin DSS rats [11, 12] and in hypertensive patients who showed enhanced salt sensitivity of blood pressure [13-15]. However, diagnosis of salt-sensitive and RAS inhibitor-resistant hypertensive patients by testing the PRA is not common because of its circadian variation, instability and impressionability [10]. Furthermore, a specific method for monitoring renin activity in the kidney is not available to date.

Recently, we have developed a new method for stably evaluating renin activity by measuring total and intact angiotensinogen (AGT) with sandwich ELISA [10, 16, 17]. In brief, the amount of des (angiotensin I) AGT can be estimated by (total AGT – intact AGT). Theoretically, the ratio of des (angiotensin I) AGT to intact

AGT reflects how much intact AGT is cleaved to des (angiotensin I) AGT by renin [10]. In the present study, we examined whether the urinary ratio of (total AGT – intact AGT) to intact AGT, a potential stable indicator of intrarenal renin activity [10], is actually suppressed in low-renin DSS hypertensive rats. We also compared the antihypertensive and renoprotective effects of MR blockade by the newly developed nonsteroidal MR blocker, esaxerenone [18, 19], with RAS blockade by the ARB, losartan, in DSS rats.

Materials and methods

Materials

The selective nonsteroidal MR blocker, esaxerenone [(S)-1-(2-Hydroxyethyl)-4-methyl-N-[4-(methylsulfonyl)phenyl]-5-[2-(trifluoromethyl) phenyl]-1H-pyrrole-3-carbox-amide] was provided by Daiichi Sankyo Co., Ltd. (Tokyo, Japan) [18, 19].

Animals

All experimental procedures were performed according to the guidelines of the Care and Use Committee of Kagawa University. Four-week-old male DSS-Iwai rats (Japan SLC, Inc., Japan), weighing 200–220 g at the beginning of the experiments, were fed a standard rat chow (0.5% NaCl) for 1 week. At 5 weeks of age, DSS rats were randomly selected to receive a normal salt diet (NS: 0.5% NaCl, n = 30) or a HS diet (8% NaCl, n = 30) for 6 weeks. At this age, the HS- and NS-fed DSS rats were also randomly divided into three groups as follows

(10 rats in each group): 1. vehicle (0.5% carboxymethyl cellulose), 2. esaxerenone (1 mg/kg/day, p.o.), 3. losartan (10 mg/kg/day, p.o.). The dosages of esaxerenone and losartan were determined based on previous studies on rats [19-21].

Blood pressure was measured by a noninvasive tail-cuff technique [6]. After a 15-min rest, systolic blood pressure (SBP) was measured at least five consecutive times on conscious rats by tail-cuff plethysmography (model BP-98A; Softron Co., Tokyo, Japan). The three lowest values were averaged. Twenty-four-hour urine sampling was performed using metabolic cages. Urine samples were stored at -30°C after centrifugation.

Sample Collection

At the end of the experiment, animals were anesthetized by isoflurane and blood was quickly collected in EDTA-containing tubes via the abdominal aorta and cooled on ice. Then, animals were euthanized by an overdose of pentobarbital (250 mg/kg, i.p.) and the kidneys were harvested. Whole blood was centrifuged

at 4°C for 10 min to separate the plasma. The kidney tissues were cut and fixed in 10% buffered paraformaldehyde or embedded in Tissue-Tek OCT compound (Sakura Finetech, Tokyo, Japan). The remaining tissues were snap frozen in liquid nitrogen. Renal cortical tissues were also collected in RNAlater and kept at 4°C overnight.

Histopathological examination

Kidneys were fixed in 10% formalin (pH 7.4), embedded in paraffin, cut into 3- μ m sections and mounted on slides. The sections were then stained with periodic acid-Schiff (PAS) or Azan reagent. Images were evaluated using light microscopy (BX-51/ DP-72; Olympus, Tokyo, Japan). PAS- and Azan-positive areas were determined using ImageJ software (National Institutes of Health, Bethesda, MD, USA) [12, 17].

Immunohistochemistry

Immunohistochemical staining of desmin [6] and 4-hydroxynonenal (4-HNE) [6]

was performed with Histofine Simple Stain MAX-PO MULTI (Nichirei Biosciences, Tokyo, Japan). After deparaffinization with xylene, sections were incubated with 0.3% hydrogen peroxide for 15 min (for desmin) or 30 min (for 4-HNE) to block endogenous peroxidases. For desmin antigen retrieval, sections were incubated for 30 min in 0.01 mol/L citrate buffer (pH 6.0) at 100°C. Proteinase K (DAKO Cytomation, Glostrup, Denmark) was used for 4-HNE antigen retrieval by incubation for 10 min. After blocking with 10% goat serum, sections were incubated overnight at 4°C with primary antibodies, each at 1:200 dilution (anti-human desmin rat monoclonal antibody, D33, DAKO Cytomation; anti-4-HNE antibody, ab46545, Abcam, Cambridge, UK). After washing sections and incubating them with secondary antibodies for 1 h at room temperature, DAB substrate (DAKO Cytomation) was used to visualize immunohistochemical staining. Finally, counterstaining was performed with hematoxylin (DAKO Cytomation). Positively stained areas were analyzed using ImageJ software.

Laser capture microdissection (LCM)

LCM was performed as previously described [6]. Frozen tissues embedded in OCT were cryosectioned into 10 μ m sections and fast-stained using an Arcturus histogene frozen section staining kit (Ambion Inc., Austin, TX, USA). For each sample, 300–400 glomeruli were captured under direct visualization with CapSure HS LCM tubes, using a laser microdissector pressure-catapulting device (Arcturus[®] LCM, Applied Biosystems, Waltham, MA, USA). From the remaining tissues, we also collected tubulointerstitial tissues. mRNA was extracted from glomerular and tubulointerstitial tissues using an RNAqueous-Micro kit (Ambion Inc.).

Real time RT-PCR

We obtained glomerular and renal interstitial tissues by the LCM technique. The mRNA levels of β -actin, transforming growth factor- β (TGF- β), type 1 collagen, *gp47^{phox}*, *p22^{pho}*, *podocin* and *nephrin* were analyzed by real-time PCR using a 7300 Fast Real-Time PCR System (Applied Biosystems, Foster City, USA) and a Light Cycler Fast Start DNA Master SYBR Green I kit (Applied Biosystems). The

rat primer sequences (forward and reverse) used were: *β-actin*,
 5'-CCCTGGCTCCTAGCACCAT-3', 5'- CCTGCTTGCTGATCCACATCT-3';
TGF-β, 5'-GCCTGAGTGGCTGTCTTTTGA-3',
 5'-GAAGCGAAAGCCCTGTATTCC-3'; *type 1 collagen*,
 5'-TCACCTACAGCACGCTTG-3', 5'-GGTCTGTTTCCAGGGTTG-3'; *gp47^{phox}*,
 5'-GGATCACAGAAGGTCCCTAGC-3', 5'-AGAAGTTCAGGGCGTTCACC-3';
p22^{phox}, 5'-TGGCCTGATCCTCATCACAG-3',
 5'-AGGCACGGACAGCAGTAAGT-3'; *podocin*,
 5'-CCTTTCCATGAGGTGGTAACCA-3', 5'-GGATGGCTTTGGA-3'; *nephrin*,
 5'-GTTTCAGCTGGGAGAGACTGG-3', 5'-AATCGGACGACAAGACGAAC-3'.

Relative mRNA levels were determined using the $2^{-\Delta\Delta Ct}$ method. The $\Delta\Delta Ct$ value was calculated using data from the NS + vehicle group.

Urinary AGT

The urinary intact and total AGT concentrations were determined using a rat AGT ELISA kit (IBL Co. Ltd., Fujioka, Japan), as previously described [17].

Other parameters

Urinary albumin and protein levels were measured using commercially available kits (Rat Albumin ELISA kit, Shibayagi, Gunma, Japan; MicroTP-test, Wako Co. Ltd., Osaka, Japan, respectively). PRA and plasma aldosterone concentrations were measured by radioimmunoassay, as previously described [5, 6, 22]. Blood urea nitrogen (BUN) concentrations were measured using a BUN assay kit (Wako Co. Ltd.).

Statistical analysis

Data are presented as means \pm SEM. One-way or two-way analysis of variance followed by Bonferroni post-test was used. $P < 0.05$ was considered statistically significant.

Results

Blood Pressure, Body Weight and Renal Function

The HS diet significantly increased the SBP (from 113 ± 2 to 236 ± 8 mmHg) of DSS rats, whereas the NS diet only exhibited a slight SBP elevation (Figure 1).

Concomitant treatment with esaxerenone significantly suppressed the HS-induced SBP elevation (203 ± 4 mmHg), while losartan did not significantly change the SBP (232 ± 4 mmHg).

At 11 weeks age, HS-treated rats showed a marked elevation in urinary volume compared with the NS-treated rats (Supplementary Table 1). Treatment with losartan or esaxerenone did not change the urinary volume, but significantly decreased the plasma BUN levels in the HS-fed DSS rats (Supplementary Table 1). The HS diet significantly increased urinary protein and albumin excretions in DSS rats. This effect was significantly suppressed by treatment with losartan or esaxerenone, however, esaxerenone had a significantly stronger effect than losartan (Supplementary Table 1).

PRA and Plasma Aldosterone Concentration

As shown in Supplementary Table 1, the HS diet significantly decreased both the PRA and the plasma aldosterone concentration in DSS rats. Treatment with losartan or esaxerenone significantly increased the PRA in both the NS- and HS-fed DSS rats. However, the plasma aldosterone levels were significantly decreased by losartan and increased by esaxerenone in the NS-fed DSS rats. In the HS-fed DSS rats, the plasma aldosterone levels tended to be decreased by losartan and increased by esaxerenone, however, these changes were not statistically significant.

Urinary AGT Excretion

In the NS-fed DSS rats, concomitant treatment with losartan or esaxerenone did not significantly change the urinary total AGT and intact AGT excretion (Figure 2A and B). We also determined the amount of des (angiotensin I) AGT, which was calculated as (total AGT – intact AGT). The ratio of (total AGT – intact AGT)

to intact AGT in the urine theoretically reflects how much intact AGT is cleaved by renin to des (angiotensin I) AGT in the kidney [10]. The results showed that neither losartan nor esaxerenone changed the ratio of (total AGT - intact AGT) to intact AGT in the NS-fed DSS rats (Figure 2C). However, the HS-fed DSS rats showed markedly greater urinary total AGT excretion ($16,968 \pm 3,943$ ng/day) compared with the NS-fed rats (306 ± 35 ng/day). Similarly, the urinary intact AGT excretion was significantly increased in the HS-fed DSS rats ($6,479 \pm 1,283$ vs. 36 ± 9 ng/day in the NS-fed DSS rats). In the HS-fed DSS rats, treatment with esaxerenone significantly decreased the urinary total AGT (from $16,968 \pm 3,943$ to $4,164 \pm 1,798$ ng/day) and the intact AGT excretion (from $6,479 \pm 1,283$ to $2,209 \pm 627$ ng/day), whereas losartan did not (Figure 2A and B). Interestingly, the HS-fed DSS rats showed a marked reduced (total AGT – intact AGT) to intact-AGT ratio in the urine ($1.3 \pm 0.1\%$) compared with the NS-fed DSS rats ($10.0 \pm 1.8\%$, Figure 2C), suggesting suppression of renin activity in the kidney. The reduced urinary ratio of des (angiotensin I) AGT to intact AGT was affected by neither losartan nor esaxerenone.

Glomerular and Tubulointerstitial Histopathological Changes

In DSS rats, the HS diet induced severe glomerular injury, as assessed by an increase in the PAS-positive areas in the glomeruli (Figure 3A). Treatment with losartan tended to attenuate the HS-induced glomerular injury, however, these changes were not statistically significant. In contrast, esaxerenone treatment induced a substantial reduction in the glomerular PAS-positive area in DSS rats (Figure 3A and B).

Glomerular podocyte injury was determined by desmin staining with immunohistochemistry [6]. The HS-fed DSS rats showed an increased glomerular desmin-positive area (Figure 4A and B). In the HS-fed DSS rats, treatment with losartan slightly but significantly decreased the glomerular desmin-positive area. We also measured the gene expression of *podocin* and *nephrin*, which are components of the slit diaphragm between adjacent podocytes in glomeruli [6]. Losartan tended to increase the glomerular *podocin* and *nephrin* mRNA levels, but these changes were not statistically significant

(Figure 4C and D). However, treatment with esaxerenone significantly decreased the glomerular desmin-positive area, and increased the glomerular mRNA levels of *podocin* and *nephrin* in HS-fed DSS rats (Figure 4A–D).

In DSS rats, the HS diet caused significant tubulointerstitial fibrosis, as assessed by quantification of the Azan-positive area in the renal interstitium (Figure 5A and B). The HS-induced tubulointerstitial fibrosis was attenuated by esaxerenone but not by losartan in HS-fed DSS (Figure 5A and B). Similarly, a significant reduction in the tubulointerstitial tissue *TGF- β* and *type 1 collagen* mRNA levels was induced by treatment with esaxerenone but not with losartan (Figure 5C and C).

Oxidative stress

Tubulointerstitial oxidative stress was evaluated by 4-HNE immunohistochemistry [6]. The HS-fed DSS rats showed a significantly increased 4-HNE-positive area in the renal interstitium (Figure 6A and B) and increased mRNA levels of the NADPH oxidase subunits, *p22^{phox}* and *gp47^{phox}*, in

tubulointerstitial tissues (Figure 6C and D). The tubulointerstitial 4-HNE-positive area was significantly decreased by losartan and esaxerenone in HS-fed DSS rats (Figure 6A and B). In these animals, losartan significantly decreased the *p22^{phox}* mRNA levels in tubulointerstitial tissues, whereas esaxerenone treatment significantly decreased both *p22^{phox}* and *gp47^{phox}* mRNA levels (Figure 6C and D).

Discussion

There is substantial evidence that low-renin salt-dependent hypertension is resistant to RAS blockade with ACEIs and ARBs [11-15], whereas treatment with MR antagonists effectively decreases blood pressure in these patients [1-7]. However, it is difficult to clinically diagnosis low-renin salt-dependent hypertension. Furthermore, so far, it is not possible to monitor intrarenal renin activity. Here, we demonstrated for the first time that HS-treated DSS rats showed a markedly reduced urinary (total AGT – intact AGT)/intact AGT ratio, suggesting suppressed intrarenal renin activity. In agreement with previous studies [11], losartan, an ARB, did not substantially decrease blood pressure in low-renin DSS hypertensive rats. In contrast, we showed that treatment with the nonsteroidal MR blocker, esaxerenone, resulted in effective blood pressure reduction in these animals. These data indicate that MR blockade with esaxerenone induces antihypertensive and renoprotective effects during the development of low-renin salt-dependent hypertension, as indicated by the

urinary (total AGT – intact AGT)/intact AGT ratio.

In subjects with low-renin salt-dependent hypertension, not only plasma renin and angiotensin II, but also plasma aldosterone levels are usually reduced [5, 10]. However, intrarenal MR was activated by HS in a ligand-independent manner through Rac1-mediated pathways, thereby contributing to the development of salt-dependent hypertension [4, 23]. Consistently, treatment with steroidal MR antagonists significantly decreased blood pressure in DSS rats, even though the plasma aldosterone levels were significantly reduced [4-7]. Recently, we have established a method for stably evaluating renin activity by measuring intact AGT and des (angiotensin I) AGT (calculated as total AGT – intact AGT) [16, 17]. Namely, the ratio of des (angiotensin I) AGT to intact AGT theoretically reflects how much intact AGT is cleaved by renin [10]. The present study showed that the ratio of des (angiotensin I) AGT to intact AGT in the urine was approximately 90% reduced by HS in DSS rats. These data indicate that the ratio of des (angiotensin I) AGT to intact AGT in the urine is a potential biomarker for identifying low-renin salt-sensitive hypertension. We also observed that

neither esaxerenone nor losartan significantly changed the ratio of urinary des (angiotensin I) AGT to intact AGT. These data suggest that during the development of HS-induced hypertension, suppressed intrarenal renin activity is not affected by treatment with esaxerenone or losartan.

A growing body of evidence has indicated that inappropriate activation of the aldosterone/MR signaling pathway induces glomerular injury [1, 3]. *In vitro* studies have shown that activation of this pathway induces mesangial cell proliferation [24, 25] and podocyte injury [6, 23]. In agreement with earlier studies that used steroidal MR antagonists, the present study showed that treatment with the nonsteroidal MR blocker [6, 26, 27], esaxerenone, induced blood pressure reduction and protective effects against glomerular injury (glomerular PAS-positive area), particularly albuminuria and podocyte injury (glomerular desmin-positive area) in DSS hypertensive rats. We also confirmed that the mRNA expression of essential podocyte components, such as *podocin* and *nephrin*, in glomerular tissues was markedly increased by treatment with esaxerenone. However, treatment with losartan did not change blood pressure

and glomerular injury, though it partially attenuated podocyte injury. The glomerular *podocin* and *nephrin* mRNA expression also tended to be increased by losartan, but these results were not statistically significant. Similarly, in agreement with a previous study [20], we demonstrated that tubulointerstitial fibrosis was significantly attenuated by treatment with esaxerenone in DSS rats. Our data also showed that the esaxerenone-induced attenuation of renal interstitial fibrosis was associated with downregulated tubulointerstitial tissue *TGF- β* and *type 1 collagen* mRNA expression. As blood pressure was significantly decreased by esaxerenone treatment, part of the renoprotective effects of esaxerenone against glomerular injury and tubulointerstitial fibrosis may be mediated by blood pressure reduction.

Both angiotensin II and aldosterone/MR stimulate oxidative stress through activation of NADPH oxidase-dependent superoxide anion production [28-30]. Several studies have also indicated that NADPH oxidase and oxidative stress play a critical role in the pathogenesis of hypertension and renal injury in DSS rats [6, 31, 32]. The present study showed that both losartan and esaxerenone

suppressed the renal interstitial oxidative stress marker, 4-NHE, as well as the expression of the tubulointerstitial tissue NADPH oxidase component, $p22^{phox}$. However, tubulointerstitial tissue $gp47^{phox}$ was significantly decreased by esaxerenone, but not by losartan. These data suggest that treatment with esaxerenone induces strong renal antioxidative effects during the development of salt-induced hypertension. Recently, Lattenist *et al.* [33] have shown that treatment with another nonsteroidal MR antagonist, finerenone, prevented the transition from acute kidney injury to chronic kidney disease, which was associated with reduced expression of oxidative stress markers, such as malondialdehyde, in renal tissues and decreased plasma 8-hydroxyguanosine concentrations. Similarly, in obese (fa/fa) Zucker rats with metabolic syndrome, the beneficial effects of finerenone against left ventricular dysfunction and proteinuria were associated with decreased myocardial oxidative stress [34]. As increased bioavailability of nitric oxide was also observed, it can be speculated that reduction in superoxide anion production would be induced by finerenone treatment [34]. Taken together, these data combined with the present results

support the concept that nonsteroidal MR blockers induce renal tissue protection by suppressing renal oxidative stress.

In the present study, we did not evaluate the difference in the beneficial effect observed between the nonsteroidal MR antagonist, esaxerenone, and steroidal MR antagonists (spironolactone or eplerenone) in DSS hypertensive rats.

However, previous pharmacokinetics studies have shown that esaxerenone elicits higher selectivity and greater binding affinity against MR than spironolactone and eplerenone, respectively [18-20]. Interestingly, recent clinical studies reported that nonsteroidal MR antagonists conferred a lower risk of hyperkalemia [35-37]. Further clinical studies are needed to confirm the beneficial effect of esaxerenone in patients with salt-dependent hypertension.

We also did not examine the combined effect of losartan and esaxerenone on renal injury in DSS hypertensive rats. Previous clinical studies have shown that adding traditional steroidal MR antagonists, such as spironolactone or eplerenone, to ACEIs or ARBs, yielded significant reductions in albuminuria in patients with CKD [1, 2]. We previously showed the additive antiproteinuric effect

of eplerenone with an ARB was associated with glomerular podocyte protection in type 2 diabetic rats [38]. However, clinical studies have also indicated a risk of hyperkalemia induced by treatment with traditional steroidal MR antagonists and ACEIs/ARBs in patients with advanced nephropathy [1, 39]. In this regard, a phase III clinical trial (ESAX-DN study) is ongoing to examine the safety and effectiveness of esaxerenone in patients with type 2 diabetic nephropathy who are treated with ACEI or with ARB (https://www.daiichisankyo.com/media_investors/media_relations/press_releases/detail/006726.html).

In conclusion, the present study suggests that the novel nonsteroidal MR blocker, esaxerenone, induced antihypertensive and renal protective effects in mice with low-renin salt-dependent hypertension through its antioxidative effects. These data support the hypothesis that nonsteroidal MR blockade is a novel therapeutic strategy for salt-sensitive hypertension and associated renal disease.

Acknowledgments:

We thank Michal Bell, PhD, from Edanz Group (www.edanzediting.com/ac) for editing the English text of a draft of this manuscript.

Conflict of interest:

This was in part a collaborative study with Daiichi-Sankyo Co., Ltd. (to A.N.). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. This study was also supported in part by the Salt Sciences Foundation (to A.N.).

REFERENCES

1. Shibata S, Ishizawa K, Uchida S. Mineralocorticoid receptor as a therapeutic target in chronic kidney disease and hypertension. *Hypertens Res.* 2017;40(3):221-5.
2. Sato A. The necessity and effectiveness of mineralocorticoid receptor antagonist in the treatment of diabetic nephropathy. *Hypertens Res.* 2015;38(6):367-74.
3. Ueda K, Nagase M. Mineralocorticoid receptor activation as an etiological factor in kidney diseases. *Clin Exp Nephrol.* 2014;18(1):16-23.
4. Shibata S, Mu S, Kawarazaki H, Muraoka K, Ishizawa K, Yoshida S, Kawarazaki W, Takeuchi M, Ayuzawa N, Miyoshi J, Takai Y, Ishikawa A, Shimosawa T, Ando K, Nagase M, Fujita T. Rac1 GTPase in rodent kidneys is essential for salt-sensitive hypertension via a mineralocorticoid receptor-dependent pathway. *J Clin Invest.* 2011;121(8):3233-43.
5. Zhu A, Yoneda T, Demura M, Karashima S, Usukura M, Yamagishi M,

- Takeda Y. Effect of mineralocorticoid receptor blockade on the renal renin-angiotensin system in Dahl salt-sensitive hypertensive rats. *J Hypertens.* 2009;27(4):800-5.
6. Kitada K, Nakano D, Liu Y, Fujisawa Y, Hitomi H, Shibayama Y, Shibata H, Nagai Y, Mori H, Masaki T, Kobori H, Nishiyama A. Oxidative stress-induced glomerular mineralocorticoid receptor activation limits the benefit of salt reduction in Dahl salt-sensitive rats. *PLoS One.* 2012;7(7):e41896.
 7. Buss SJ, Backs J, Kreusser MM, Hardt SE, Maser-Gluth C, Katus HA, Haass M. Spironolactone preserves cardiac norepinephrine reuptake in salt-sensitive Dahl rats. *Endocrinology.* 2006;147(5):2526-34.
 8. Hood SJ, Taylor KP, Ashby MJ, Brown MJ. The spironolactone, amiloride, losartan, and thiazide (SALT) double-blind crossover trial in patients with low-renin hypertension and elevated aldosterone-renin ratio. *Circulation.* 2007;116(3):268-75.
 9. Kimura G, Dohi Y, Fukuda M. Salt sensitivity and circadian rhythm of

blood pressure: the keys to connect CKD with cardiovascular events.

Hypertens Res. 2010;33(6):515-20.

10. Nishiyama A, Kobori H. Independent regulation of renin-angiotensin-aldosterone system in the kidney. *Clin Exp Nephrol.* 2018; In-press.
11. Takahashi H, Nakagawa S, Wu Y, Kawabata Y, Numabe A, Yanagi Y, Tamaki Y, Uehara Y, Araie M. A high-salt diet enhances leukocyte adhesion in association with kidney injury in young dahl salt-sensitive rats. *Hypertens Res.* 2017;40(11):912-20.
12. Guo P, Nishiyama A, Rahman M, Nagai Y, Noma T, Namba T, Ishizawa M, Murakami K, Miyatake A, Kimura S, Mizushige K, Abe Y, Ohmori K, Kohno M. Contribution of reactive oxygen species to the pathogenesis of left ventricular failure in Dahl salt-sensitive hypertensive rats: effects of angiotensin II blockade. *J Hypertens.* 2006;24(6):1097-104.
13. Shimamoto K, Ando K, Fujita T, Hasebe N, Higaki J, Horiuchi M, Imai Y, Imaizumi T, Ishimitsu T, Ito M, Ito S, Itoh H, Iwao H, Kai H, Kario K,

Kashihara N, Kawano Y, Kim-Mitsuyama S, Kimura G, Kohara K, Komuro I, Kumagai H, Matsuura H, Miura K, Morishita R, Naruse M, Node K, Ohya Y, Rakugi H, Saito I, Saitoh S, Shimada K, Shimosawa T, Suzuki H, Tamura K, Tanahashi N, Tsuchihashi T, Uchiyama M, Ueda S, Umemura S; Japanese Society of Hypertension Committee for Guidelines for the Management of Hypertension. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). *Hypertens Res.* 2014;37(4):253-390.

14. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC Jr, Svetkey LP, Taler SJ, Townsend RR, Wright JT Jr, Narva AS, Ortiz E. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). *JAMA.* 2014;311(5):507-20.
15. Lindhorst J, Alexander N, Blignaut J, Rayner B. Differences in hypertension between blacks and whites: an overview. *Cardiovasc J Afr.*

2007;18(4):241-47.

16. Yoshimoto T, Furuki T, Kobori H, Miyakawa M, Imachi H, Murao K, Nishiyama A. Effects of sodium-glucose cotransporter 2 inhibitors on urinary excretion of intact and total angiotensinogen in patients with type 2 diabetes. *J Investig Med.* 2017;65(7):1057-61.
17. Li L, Konishi Y, Morikawa T, Zhang Y, Kitabayashi C, Kobara H, Masaki T, Nakano D, Hitomi H, Kobori H, Nishiyama A. Effect of a SGLT2 inhibitor on the systemic and intrarenal renin-angiotensin system in subtotaly nephrectomized rats. *J Pharmacol Sci.* 2018;137(2):220-3.
18. Yamada M, Takei M, Suzuki E, Takakusa H, Kotsuma M, Washio T, Murayama N, Inoue SI, Izumi T. Pharmacokinetics, distribution, and disposition of esaxerenone, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist, in rats and monkeys. *Xenobiotica.* 2017;47(12):1090-103.
19. Arai K, Homma T, Morikawa Y, Ubukata N, Tsuruoka H, Homma T. Pharmacological profile of CS-3150, a novel, highly potent and selective

- non-steroidal mineralocorticoid receptor antagonist. *Eur J Pharmacol.* 2015;761:226-34.
20. Arai K, Tsuruoka H, Homma T. CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats. *Eur J Pharmacol.* 2015;769:266-73.
21. Karanovic D, Grujic-Milanovic J, Miloradovic Z, Ivanov M, Jovovic D, Vajic UJ, Zivotic M, Markovic-Lipkovski J, Mihailovic-Stanojevic N. Effects of Single and Combined Losartan and Tempol Treatments on Oxidative Stress, Kidney Structure and Function in Spontaneously Hypertensive Rats with Early Course of Proteinuric Nephropathy. *PLoS One.* 2016;11(8):e0161706.
22. Nishiyama A, Seth DM, Navar LG. Renal interstitial fluid angiotensin I and angiotensin II concentrations during local angiotensin-converting enzyme inhibition. *J Am Soc Nephrol.* 2002;13(9):2207-12.
23. Shibata S, Nagase M, Yoshida S, Kawarazaki W, Kurihara H, Tanaka H,

- Miyoshi J, Takai Y, Fujita T. Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. *Nat Med*. 2008;14(12):1370-76.
24. Nishiyama A, Yao L, Fan Y, Kyaw M, Kataoka N, Hashimoto K, Nagai Y, Nakamura E, Yoshizumi M, Shokoji T, Kimura S, Kiyomoto H, Tsujioka K, Kohno M, Tamaki T, Kajiya F, Abe Y. Involvement of aldosterone and mineralocorticoid receptors in rat mesangial cell proliferation and deformability. *Hypertension*. 2005;45(4):710-6.
25. Terada Y, Kobayashi T, Kuwana H, Tanaka H, Inoshita S, Kuwahara M, Sasaki S. Aldosterone stimulates proliferation of mesangial cells by activating mitogen-activated protein kinase 1/2, cyclin D1, and cyclin A. *J Am Soc Nephrol*. 2005;16(8):2296-305.
26. Kawarazaki H, Ando K, Nagae A, Fujita M, Matsui H, Fujita T. Mineralocorticoid receptor activation contributes to salt-induced hypertension and renal injury in prepubertal Dahl salt-sensitive rats. *Nephrol Dial Transplant*. 2010;25(9):2879-89.

27. Nagase M, Shibata S, Yoshida S, Nagase T, Gotoda T, Fujita T. Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker. *Hypertension*. 2006;47(6):1084-93.
28. Hitomi H, Kiyomoto H, Nishiyama A. Angiotensin II and oxidative stress. *Curr Opin Cardiol*. 2007;22(4):311-5.
29. Nishiyama A, Yao L, Nagai Y, Miyata K, Yoshizumi M, Kagami S, Kondo S, Kiyomoto H, Shokoji T, Kimura S, Kohno M, Abe Y. Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone/salt-induced hypertensive rats. *Hypertension*. 2004;43(4):841-8.
30. Miyata K, Rahman M, Shokoji T, Nagai Y, Zhang GX, Sun GP, Kimura S, Yukimura T, Kiyomoto H, Kohno M, Abe Y, Nishiyama A. Aldosterone stimulates reactive oxygen species production through activation of NADPH oxidase in rat mesangial cells. *J Am Soc Nephrol*. 2005;16(10):2906-12.
31. Nishiyama A, Yoshizumi M, Hitomi H, Kagami S, Kondo S, Miyatake A,

Fukunaga M, Tamaki T, Kiyomoto H, Kohno M, Shokoji T, Kimura S, Abe Y.

The SOD mimetic tempol ameliorates glomerular injury and reduces mitogen-activated protein kinase activity in Dahl salt-sensitive rats. *J Am Soc Nephrol.* 2004;15(2):306-15.

32. Onozato ML, Tojo A, Kobayashi N, Goto A, Matsuoka H, Fujita T. Dual blockade of aldosterone and angiotensin II additively suppresses TGF-beta and NADPH oxidase in the hypertensive kidney. *Nephrol Dial Transplant.* 2007;22(5):1314-22.
33. Lattenist L, Lechner SM, Messaoudi S, Le Mercier A, El Moghrabi S, Prince S, Bobadilla NA, Kolkhof P, Jaisser F, Barrera-Chimal J. Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Protects Against Acute Kidney Injury-Mediated Chronic Kidney Disease: Role of Oxidative Stress. *Hypertension.* 2017;69(5):870-8.
34. Lachaux M, Barrera-Chimal J, Nicol L, Rémy-Jouet I, Renet S, Dumesnil A, Wecker D, Richard V, Kolkhof P, Jaisser F, Ouvrard-Pascaud A, Mulder P. Short- and long-term administration of the non-steroidal

- mineralocorticoid receptor antagonist finerenone opposes metabolic syndrome-related cardio-renal dysfunction. *Diabetes Obes Metab.* 2018;20(10):2399-407.
35. Kato M, Furuie H, Shimizu T, Miyazaki A, Kobayashi F, Ishizuka H. Single- and multiple-dose escalation study to assess pharmacokinetics, pharmacodynamics and safety of oral esaxerenone in healthy Japanese subjects. *Br J Clin Pharmacol.* 2018;84(8):1821-9.
36. Pei H, Wang W, Zhao D, Wang L, Su GH, Zhao Z. The use of a novel non-steroidal mineralocorticoid receptor antagonist finerenone for the treatment of chronic heart failure: A systematic review and meta-analysis. *Medicine (Baltimore).* 2018;97(16):e0254.
37. Pitt B, Kober L, Ponikowski P, Gheorghide M, Filippatos G, Krum H, Nowack C, Kolkhof P, Kim SY, Zannad F. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. *Eur Heart J.*

2013;34(31):2453-63.

38. Nishiyama A, Kobori H, Konishi Y, Morikawa T, Maeda I, Okumura M, Kishida M, Hamada M, Nagai Y, Nakagawa T, Ohashi N, Nakano D, Hitomi H, Imanishi M. Mineralocorticoid receptor blockade enhances the antiproteinuric effect of an angiotensin II blocker through inhibiting podocyte injury in type 2 diabetic rats. *J Pharmacol Exp Ther.* 2010 Mar;332(3):1072-80.
39. Nishiyama A. Pathophysiological mechanisms of mineralocorticoid receptor-dependent cardiovascular and chronic kidney disease. *Hypertens Res.* 2018; In-press.

FIGURE LEGENDS

Figure 1. Changes in systolic blood pressure (SBP) in Dahl salt-sensitive (DSS) rats.

NS, normal salt; HS, high salt. Values are expressed as means \pm SEM. * $P < 0.05$ vs. NS + vehicle. # $P < 0.05$, HS + vehicle vs. HS + esaxerenone. † $P < 0.05$, HS + losartan vs. HS + esaxerenone.

Figure 2. Urinary angiotensinogen (AGT) in DSS rats.

A, Urinary total AGT excretion. B, Urinary intact AGT excretion. C, The ratio of (total AGT – intact AGT) to intact AGT in the urine. * $P < 0.05$ vs. NS + vehicle. # $P < 0.05$, HS + vehicle vs. HS + esaxerenone. † $P < 0.05$, HS + losartan vs. HS + esaxerenone.

Figure 3. Glomerular injury in DSS rats.

A, Representative images of periodic acid Schiff (PAS)-stained renal sections.

Original magnification, $\times 200$. B, Quantitative analysis of the PAS-positive area in the glomerulus. $**P < 0.05$ vs. NS + vehicle. $\#P < 0.05$, HS + vehicle vs. HS + esaxerenone.

Figure 4. Glomerular podocyte injury in DSS rats.

A, Representative micrographs of desmin-stained renal sections. Original magnification, $\times 200$. B, Quantitative analysis of the desmin-positive area in the glomerulus. C, mRNA expression of *podocin*. D, mRNA expression of *nephrin*.

The $\Delta\Delta\text{Ct}$ value was calculated using data from the NS + vehicle group. $*P < 0.05$ vs. NS + vehicle. $\#P < 0.05$, HS + vehicle vs. HS + losartan or HS + esaxerenone. $^\dagger P < 0.05$, HS + losartan vs. HS + esaxerenone.

Figure 5. Tubulointerstitial fibrosis in DSS rats.

A, Representative images of Azan-stained renal sections. Original magnification, $\times 200$. B, Quantitative analysis of the Azan-positive area. C, mRNA expression of *transforming growth factor β (TGF- β)*. D, mRNA expression of *type 1 collagen*

(*collagen-1*). The $\Delta\Delta\text{Ct}$ value was calculated using data from the NS + vehicle group. * $P < 0.05$ vs. NS + vehicle. # $P < 0.05$, HS + vehicle vs. HS + esaxerenone. † $P < 0.05$, HS + losartan vs. HS + esaxerenone.

Figure 6. Renal oxidative stress in DSS rats.

A, Representative micrographs of 4-hydroxynonenal (4-HNE)-stained renal sections. Original magnification, $\times 200$. B, Quantitative analysis of the 4-HNE-positive area in renal interstitium. C, mRNA expression of *p22^{phox}*. D, mRNA expression of *gp47^{phox}*. The $\Delta\Delta\text{Ct}$ value was calculated using data from the NS + vehicle group. * $P < 0.05$ vs. NS + vehicle. # $P < 0.05$, HS + vehicle vs. HS + losartan or HS + esaxerenone. † $P < 0.05$, HS + losartan vs. HS + esaxerenone.

Fig. 1




Fig. 2





Fig. 3

A



B






Fig. 4


A



B



C



D






Fig. 5


A



B



C



D








Fig. 6



Supplementary Table 1. Body, plasma and urinary parameters at 11 weeks of age.

	NS + vehicle (n = 10)	NS + losartan (n = 10)	NS + esaxerenone (n = 10)	HS + vehicle (n = 10)	HS + losartan (n = 10)	HS + esaxerenone (n = 10)
Body weight (g)	334 ± 4	332 ± 2	337 ± 3	294 ± 3*	318 ± 5	306 ± 7
Urine volume (mL/24 h)	8.5 ± 1.0	10.0 ± 0.8	9.2 ± 1.4	64.3 ± 2.2*	59.6 ± 3.7*	56.2 ± 4.1*
Plasma BUN (mg/dL)	21.2 ± 2.2	22.9 ± 2.0	20.9 ± 2.4	37.3 ± 7.5*	23.4 ± 2.3 [#]	24.2 ± 3.5 [#]
Urinary total protein excretion (mg/day)	11.3 ± 1.4	6.5 ± 0.8*	10.2 ± 0.8	292.8 ± 41.3*	231.1 ± 38.2* [#]	64.0 ± 22.2* ^{#†}
Urinary albumin excretion (mg/day)	1.5 ± 0.2	0.8 ± 0.2*	1.4 ± 0.1	42.6 ± 4.1*	32.2 ± 1.9* [#]	19.6 ± 4.3* ^{#†}
Plasma renin activity (ng/mL h)	4.6 ± 0.8	8.2 ± 1.0*	6.7 ± 0.9*	0.9 ± 0.2*	3.3 ± 0.6 [#]	1.8 ± 0.4* ^{#†}
Plasma aldosterone concentration (pg/mL)	276 ± 39	181 ± 27*	486 ± 52*	82 ± 11*	61 ± 8*	102 ± 12*

Values are means ± SEM. NS, normal salt; HS, high salt. *P < 0.05 vs. NS + vehicle. [#]P < 0.05; HS + vehicle vs. HS + losartan or HS + esaxerenone. [†]P < 0.05; HS + losartan vs. HS + esaxerenone.